Nociceptin/Orphanin FQ
Nociceptin (Orphanin FQ, N/OFQ) is a 17-amino-acid neuropeptide that signals through the NOP receptor (ORL-1). Structurally related to dynorphin but functionally distinct from classical opioids, it modulates pain, stress, anxiety, and addiction through complex, often anti-opioid mechanisms.
Nociceptin (also known as Orphanin FQ, abbreviated N/OFQ) is a 17-amino-acid neuropeptide discovered simultaneously by two groups in 1995 as the endogenous ligand for the previously orphaned opioid-like receptor ORL-1, now designated the nociceptin/orphanin FQ peptide (NOP) receptor. Despite striking structural homology to dynorphin A — sharing a conserved FGGF N-terminal motif with the opioid peptide's YGGF — nociceptin does not bind μ (MOP), δ (DOP), or κ (KOP) opioid receptors at physiological concentrations, and the NOP receptor does not bind classical opioid peptides.
Overview
Nociceptin was discovered in 1995 independently by Meunier et al. (who named it nociceptin for its ability to lower pain thresholds when given intracerebroventricularly in mice) and by Reinscheid et al. (who named it orphanin FQ, reflecting its status as an orphan receptor ligand with phenylalanine and glutamine as terminal residues). Meunier JC et al. (1995) — Nature 377, 532-535.
The NOP receptor is a class A GPCR that couples primarily to Gi/o proteins, inhibiting adenylyl cyclase, activating GIRK potassium channels, and inhibiting voltage-gated calcium channels — the same intracellular signaling cascade used by classical opioid receptors. Despite this shared signaling, the NOP system functions largely as a functional anti-opioid system at supraspinal levels, opposing morphine-induced analgesia, reward, and tolerance.
The nociceptin/NOP system is widely distributed throughout the central nervous system, with highest densities in the cortex, hippocampus, amygdala, hypothalamus, brainstem, and spinal cord. Peripheral expression includes immune cells, gastrointestinal tract, and airways. This broad distribution underlies nociceptin's involvement in diverse physiological processes: pain modulation (with bidirectional effects depending on dose, route, and pain model), stress and anxiety, learning and memory, food intake, and reward/addiction.
Mechanism of Action
NOP Receptor Signaling: Nociceptin binds the NOP receptor with nanomolar affinity, activating Gi/o-mediated signaling: inhibition of adenylyl cyclase (reducing cAMP), activation of GIRK channels (membrane hyperpolarization), inhibition of N-type and P/Q-type voltage-gated calcium channels (reduced neurotransmitter release), and activation of MAPK pathways. This signaling profile is virtually identical to that of μ-opioid receptor activation, yet the functional consequences are often opposite. Mollereau C et al. (1994) — FEBS Lett. 341, 33-38.
Supraspinal Anti-Opioid Effects: At supraspinal levels (periaqueductal gray, rostral ventromedial medulla), nociceptin functionally opposes opioid analgesia. Intracerebroventricular (ICV) nociceptin is hyperalgesic — it lowers pain thresholds and reverses morphine-induced analgesia. This occurs because nociceptin inhibits the same descending pain-inhibitory neurons that opioids activate. By hyperpolarizing neurons in the periaqueductal gray through GIRK channel activation, nociceptin suppresses the descending inhibitory output that normally reduces spinal pain transmission. Mogil JS et al. (1996) — Neuroscience 75, 333-337.
Spinal Pro-Nociceptive and Anti-Nociceptive Effects: At the spinal level, nociceptin has predominantly anti-nociceptive (analgesic) effects, inhibiting spinal pain transmission through presynaptic inhibition of primary afferent neurotransmitter release and postsynaptic hyperpolarization of dorsal horn neurons. The bidirectional pain modulation — hyperalgesia supraspinally but analgesia spinally — is a hallmark of the nociceptin system and complicates therapeutic development.
Stress and Anxiety Modulation: Nociceptin has potent anxiolytic effects, opposing the stress-promoting actions of corticotropin-releasing factor (CRF). NOP receptor activation in the amygdala and bed nucleus of the stria terminalis reduces anxiety-like behavior in animal models. Stress exposure increases nociceptin release, suggesting it serves as an endogenous stress-buffering system. Witkin JM et al. (2014) — Pharmacol Ther. 141, 68-80.
Anti-Reward and Addiction: Nociceptin opposes the rewarding effects of drugs of abuse by inhibiting mesolimbic dopamine transmission. NOP receptor agonists reduce alcohol self-administration, cocaine-seeking behavior, and opioid reward in preclinical models. This anti-reward property has made the NOP receptor an attractive target for addiction therapeutics. The mechanism involves nociceptin-mediated inhibition of dopamine neurons in the ventral tegmental area (VTA) and inhibition of dopamine release in the nucleus accumbens.
Feeding Regulation: Central nociceptin administration stimulates food intake, an effect mediated through hypothalamic circuits. Unlike opioid-driven feeding (hedonic, reward-based), nociceptin-driven feeding appears to involve homeostatic hunger circuits.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Structural Relationship to Opioid Peptides
Nociceptin's sequence (FGGFTGARKSARKLANQ) is remarkably similar to dynorphin A (YGGFLRRIRPKLKWDNQ). Both share the -GGF- motif at positions 2-4 and a polycationic C-terminal region. The critical difference is the N-terminal residue: nociceptin has phenylalanine (F) while all classical opioid peptides have tyrosine (Y). This single difference — the loss of the tyrosine hydroxyl group — largely accounts for nociceptin's inability to bind classical opioid receptors. Conversely, replacing nociceptin's Phe1 with Tyr converts it into a peptide with mixed NOP/opioid receptor activity. The NOP receptor's binding pocket accommodates phenylalanine but not tyrosine, providing the structural basis for the pharmacological separation of the nociceptin and opioid systems.
NOP Agonists for Addiction
The anti-reward properties of nociceptin have driven development of NOP receptor agonists for alcohol and substance use disorders. Preclinical studies show that NOP agonists reduce alcohol consumption, prevent relapse-like drinking behavior, and attenuate the rewarding effects of cocaine and morphine without producing reward themselves (NOP agonists are not self-administered by animals). Several NOP agonists have been explored in early-stage clinical development. The challenge is achieving anti-reward effects without the hyperalgesic and motor-inhibitory effects of central NOP activation.
NOP Receptor and Anxiety
NOP receptor agonists produce anxiolytic effects comparable to benzodiazepines in preclinical models (elevated plus maze, stress-induced hyperthermia, fear-potentiated startle) without sedation, motor impairment, or abuse liability. The anxiolytic mechanism involves inhibition of CRF release in the amygdala and reduced noradrenergic activation in the locus coeruleus. Conversely, NOP receptor knockout mice display increased anxiety-like behavior. These findings have prompted interest in NOP agonists as novel anxiolytics, though clinical development for anxiety indications remains early-stage.
Cebranopadol — Dual NOP/MOP Agonist
Cebranopadol (GRT-6005, Grünenthal) is a first-in-class dual NOP/μ-opioid receptor agonist that exploits the distinct anatomical distributions and functional properties of both receptors to produce analgesia with potentially reduced opioid-like side effects. By simultaneously activating NOP receptors (which oppose reward and respiratory depression at certain sites) and μ-opioid receptors (which produce analgesia), cebranopadol aims to achieve strong analgesia with reduced abuse liability, tolerance development, and respiratory depression compared to pure μ-opioid agonists. Phase 2 and 3 clinical trials have evaluated cebranopadol in chronic low back pain, diabetic neuropathic pain, and cancer pain. Linz K et al. (2014) — J Pharmacol Exp Ther. 349, 535-548.
Pain Modulation Complexity
The bidirectional effects of nociceptin on pain have been extensively studied. ICV nociceptin at doses of 1-10 nmol produces hyperalgesia in acute thermal pain models (tail-flick, hot plate) by opposing descending inhibition from the periaqueductal gray. However, intrathecal nociceptin produces dose-dependent analgesia, particularly effective against inflammatory and neuropathic pain. Low supraspinal doses (<0.1 nmol ICV) can be analgesic rather than hyperalgesic, suggesting a bell-shaped dose-response curve. In chronic pain models (nerve injury, inflammation), the balance shifts toward anti-nociceptive effects of nociceptin, partly because chronic pain states alter NOP receptor expression and nociceptin release. Meunier JC et al. (1995) — PMID: 7566152
Safety Profile
Nociceptin is an endogenous neuropeptide not administered therapeutically. Safety considerations relate to NOP-targeting drugs. NOP agonists at high central doses produce hyperalgesia (supraspinal), motor impairment, and sedation in animal models. Cebranopadol, as a dual NOP/MOP agonist, carries opioid-related risks including respiratory depression, constipation, nausea, and potential for physical dependence, though preclinical data suggest reduced abuse liability compared to pure μ-opioid agonists due to the NOP component opposing reward. NOP antagonists could theoretically increase anxiety and stress reactivity (removing the endogenous stress-buffering system). The NOP system's complexity — opposing effects at different anatomical levels — means that systemic NOP-targeting drugs produce composite effects that are difficult to predict from site-specific studies. Long-term effects of chronic NOP modulation on pain sensitivity, stress resilience, and neuroendocrine function remain under investigation.
Clinical Research Protocols
Cebranopadol Dosing (Clinical Trials):
- Chronic Low Back Pain: 200-600 μg/day oral, titrated over 4-8 weeks. Phase 3 trials evaluated 200-400 μg maintenance doses.
- Diabetic Neuropathic Pain: 200-600 μg/day oral. Demonstrated significant pain reduction vs. placebo.
- Cancer Pain: Studied as alternative to strong opioids in opioid-naive and opioid-experienced patients.
NOP Receptor Imaging: [¹¹C]-NOP-1A PET tracer allows in vivo quantification of NOP receptor availability in human brain. Used to study NOP receptor changes in pain, addiction, and psychiatric disorders.
Nociceptin Measurement: Cerebrospinal fluid (CSF) nociceptin measured by radioimmunoassay or ELISA. Elevated in chronic pain states, altered in substance use disorders and psychiatric conditions. Plasma nociceptin is less reliable due to peripheral sources and rapid degradation.
Preclinical Pain Models: Nociceptin's pain effects are studied using ICV (supraspinal), intrathecal (spinal), and peripheral administration routes. Tail-flick, hot plate, von Frey, and formalin tests are standard assays. Route-specific effects must be considered when interpreting results.
Pharmacokinetic Profile
- Half-life
- Minutes (rapidly degraded by aminopeptidases)
Ongoing & Future Research
-
Active areas of nociceptin/NOP research include:
-
Cebranopadol Clinical Development: Ongoing Phase 3 trials for chronic pain indications. The key question is whether dual NOP/MOP agonism provides clinically meaningful advantages (reduced abuse liability, reduced tolerance) over conventional opioids.
-
NOP Agonists for Alcohol Use Disorder: NOP agonists have shown robust preclinical efficacy in reducing alcohol consumption. Clinical trials are needed to determine whether these effects translate to human alcohol use disorder.
-
NOP Receptor Partial Agonists: Full NOP agonists produce both desirable (anti-anxiety, anti-reward) and undesirable (hyperalgesia, motor impairment) effects. Partial agonists or biased agonists that selectively activate beneficial signaling pathways are under development.
-
NOP System in Chronic Pain: The shift from pro-nociceptive (acute pain) to anti-nociceptive (chronic pain) roles of the nociceptin system is being investigated at the molecular level. Understanding this shift could inform pain-state-specific NOP-targeted therapies.
-
Nociceptin in Psychiatric Disorders: Altered NOP system function has been reported in depression, PTSD, and schizophrenia. NOP receptor imaging (PET) in patient populations is clarifying the role of this system in psychiatric pathophysiology.
-
Nociceptin-Opioid Interactions in Tolerance: NOP agonists can prevent or reverse μ-opioid receptor tolerance in animal models. Research is exploring whether NOP activation could be used as an adjunct to opioid therapy to maintain analgesic efficacy during chronic treatment.
Research Protocols
intrathecal Injection
However, intrathecal nociceptin produces dose-dependent analgesia, particularly effective against inflammatory and neuropathic pain. Preclinical Pain Models: Nociceptin's pain effects are studied using ICV (supraspinal), intrathecal (spinal), and peripheral administration routes.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Phase 3 | 200-400 μg | Per protocol | — |
intracerebroventricular Injection
(who named it nociceptin for its ability to lower pain thresholds when given intracerebroventricularly in mice) and by Reinscheid et al. Intracerebroventricular (ICV) nociceptin is hyperalgesic — it lowers pain thresholds and reverses morphine-induced analgesia.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Phase 3 | 200-400 μg | Per protocol | — |
oral
Clinical Research Protocols Cebranopadol Dosing (Clinical Trials): - Chronic Low Back Pain: 200-600 μg/day oral, titrated over 4-8 weeks. - Diabetic Neuropathic Pain: 200-600 μg/day oral.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Chronic Low Back Pain | 200-600 μg, 200-400 μg | Per protocol | 4-8 weeks(Route: Oral) |
| Diabetic Neuropathic Pain | 200-600 μg | Per protocol | —(Route: Oral) |
Interactions
Peptide Interactions
The cebranopadol approach combines NOP agonism with μ-opioid agonism. The NOP component may reduce opioid-induced reward (opposing dopaminergic activation in VTA/NAc), reduce tolerance development (NOP agonists block some mechanisms of μ-opioid tolerance), and modify respiratory depression (NOP activation at certain brainstem sites may partially counteract μ-opioid respiratory depression). This combination rationale is unique in pain pharmacology.
NOP Agonists + CRF Antagonists: Both systems modulate stress and anxiety through overlapping circuits in the amygdala. Combined NOP agonism and CRF antagonism could provide enhanced anxiolytic effects, though this combination remains preclinical.
NOP Agonists + Naltrexone (Addiction): Combining NOP agonism (reducing reward/craving) with μ-opioid antagonism (blocking opioid effects) is a theoretical approach for opioid use disorder, though not yet tested clinically.
Nociceptin + CGRP: Nociceptin modulates trigeminal nociceptive processing and may interact with CGRP-mediated pain signaling in migraine. NOP receptors are expressed in trigeminal ganglia, where nociceptin inhibits CGRP release. This interaction has implications for migraine therapeutics.
Quality Indicators
What to look for
- Phase 3 clinical trial data available
- Multiple peer-reviewed studies available
- Extensive preclinical data
Frequently Asked Questions
References (7)
- [7]
- [1]Meunier, J. C. et al Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Nature (1995)
- [2]Mollereau, C. et al ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization FEBS Lett. (1994)
- [3]Toll, L. et al Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems Pharmacol Rev. (2016)
- [4]Witkin, J. M. et al The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence Pharmacol Ther. (2014)
- [5]Linz, K. et al Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist J Pharmacol Exp Ther. (2014)
- [6]Calo, G. et al Pharmacology of nociceptin and its receptor: a novel therapeutic target Br J Pharmacol. (2000)
NGF (Nerve Growth Factor)
Nerve Growth Factor (NGF) is a neurotrophic protein essential for the survival, maintenance, and differentiation of sympathetic and sensory neurons. It signals through TrkA and p75NTR receptors and is a major research target in Alzheimer's disease, chronic pain, and corneal nerve regeneration.
Nonapeptide-1
Nonapeptide-1 (Melanostatine-5) is an MSH antagonist peptide that competes for MC1R receptor binding to inhibit melanin synthesis, used in skin brightening and pigmentation correction products.